type 2 diabetes
Gan & Lee Doses First Patient in Oral GLP-1 Pill Trial
Gan & Lee Pharmaceuticals Co., Ltd. (SSE: 603087.SH) announced on September 9 that the first participant has been dosed in a first-in-human Phase 1 study of GZC8072, an experimental once-weekly oral peptide GLP-1 receptor agonist, marking the compound’s formal entry into human testing. This is an early, safety-focused milestone, not an efficacy result, and no…
